



Osteoporosis

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report Osteoporosis Q1 2011

Therapeutic Class:	Metabolic Disorders
Focus Area:	Osteoporosis
Specialty/Location:	Endocrinologists, Rheumatologists / Europe, N. America
Number of Interviews:	6
Number of Pages:	147
Publication Date:	April 2011
Principal Authors:	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
Product Code:	MBOQ111-51
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract: Osteoporosis Thought Leader Panel #51 takes a different tack from its recent predecessors. In this series of interviews with our panel of rheumatologists and endocrinologists who specialize in the treatment of non-malignant bone loss, we specifically constrain their comments to take cost into consideration. The fact is that osteoporosis is a disease that can be managed by a myriad of therapeutic treatment approaches. Bisphosphonates have been available for 25 years. We have SERMs, HRT, calcitonin, PTH, strontium, calcium, and a host of new therapeutics in the pipeline. Treatment of bone loss is now a mature art, and payers are not swayed by esoteric arguments related to “hydration shells associated with strontium metal intercalation” or “improvement in bone microarchitecture blah blah blah”. What they are responding to is “number needed to treat in order to prevent some system cost of treatment”.

Therefore... our executive summary for this report divides existing and pipeline therapeutics into known and expected cost-of-therapy cohorts, and compares the efficacy, safety and convenience benefits for those therapies that fall into each cohort. Specifically, we compare zoledronic acid vs denosumab, marketed oral antiresorptives (branded BPs, generic BPs, SERMs), near-market oral antiresorptives (cathepsin K, strontium, oral calcitonin), and anabolics (teriparatide, anti-sclerostin).

Drugs/Mechanisms Discussed in this Report:

Company	Generic	Brand
Abbott / Piramal	zoledronic acid	Zolephos
Amgen / GSK	denosumab AMG-167	Prolia
Amgen / UCB	AMG-785 (CDP-7851; Anti-Sclerostin MAb)	
generic	nitroglycerine	
Lilly	teriparatide raloxifene antisclerostin MAb	Forteo / Forsteo Evista
Merck	alendronate odanacatib	Fosamax
Novartis	zoledronic acid	Reclast / Aclasta / Zometa
Novartis / Nordic / Emisphere / Unigene	SMC-021; oral calcitonin	Enteripep
Ono	ONO-5334	
Pfizer	bazedoxifene +/- estrogen TSEC	Viviant / Aprela
Roche	ibandronate	Boniva
Servier	strontium ranelate	Protelos
Teva	raloxifene	Raloxifene Teva
Teva, Watson, Barr, others	alendronate	
Warner Chilcott	risedronate	Actonel / Atelvia

Table of Contents

Executive Summary	3
Report Highlights.....	5
Key Findings	17
To Treat or Not To Treat	17
Antiresorptive Holidays.....	19
Vert, Wrist, Shoulder Fractures	23
Hip Fractures.....	25
Prior Authorization	26
Denosumab vs Zoledronic Acid.....	26
No Advantage.....	26
Favors Zoledronic Acid.....	27
Favors denosumab.....	33
Oral Bisphosphonates	40
Generic Alendronate (Watson, Barr, Teva, others)	44
Atelvia / Actonel	46
Boniva (ibandronate; Roche)	47
Cathepsin K.....	49
odanacatib (Merck)	49
ONO-5334 (Ono)	56
Sclerostin vs PTH.....	58
Forteo (teriparatide; Lilly)	58
AMG-785 / CDP7851 (Amgen / UCB), AMG-167 (Amgen / UCB)	64
anti-sclerostin MAb; Lilly	69
SERMs, Strontium, Oral Calcitonin	74
SERMs	74
Raloxifene Teva (Teva).....	75
Evista (raloxifene; Lilly)	76
Viviant / Aprela (bazedoxifene +/- estrogen TSEC; Pfizer)	76
Strontium	79
Protelos (strontium ranelate; Servier)	79
Calcitonin.....	83
Enteripep; SMC-021 (Nordic / Novartis / Unigene / Emisphere)	83
Nitroglycerine	87
Thought Leader Transcripts	88
Interview BJE02552	88
Interview BJE02553	97
Interview BJE02554	108
Interview BJE02555	118
Interview BJE02556	129
Interview BJE02557	138